Retrospective cohort study reveals real-world medication patterns in adults with migraine, highlighting treatment needs for anti-CGRP pathway monoclonal antibodies.
Migraine is a debilitating neurological disorder, with a wide range of symptoms and disease burden, underscoring the heterogeneity of patients' disease characteristics and treatment needs. To characterize the profile of migraine patients in the US who may be eligible for preventive treatment with an anti-CGRP pathway mAb and to better understand treatment patterns and real-world use of acute and preventive medications for migraine, we conducted a retrospective cohort study of adult patients.
No takes yet. Share an insight, caveat, or question.
Khodavirdi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: